NTRA vs PTGX
Natera, Inc. vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
VS
PTGX
Protagonist Therapeutics, Inc.
67
Buy
| Metric | NTRA | PTGX |
|---|
| AI Score |
67
|
67
|
| Price |
$314.33
|
$158.59
|
| P/E Ratio |
-227.89×
|
127.33×
|
| ROE |
-12.2%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
65.3%
|
99.9%
|
| Debt / Equity |
0.13×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
65.5
|
75.9
|
| Beta |
1.514
|
1.794
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for NTRA versus PTGX.
The committee scores are tied.
NTRA and PTGX both score 67/100.
NTRA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 37.8% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Price-to-book of 18.5x prices in significant intangible value — Value
- ROE of only -11.7% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 34.9% signals elevated volatility — Risk
PTGX Committee View
83% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 119.8 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 119.8 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- RSI at 76 is in overbought territory — Technical